The 216th Co-Investing Atrium will take place on April 3rd, 2025, bringing together a curated circle of up to 15 international investors to: 

- Engage in networking, one-to-one meetings with each other
- Share opinions on the sector during an interactive round table
- Explore a high-impact, late-stage opportunity in the rapidly advancing field of cancer diagnostics. 

The agenda of the gathering:
 

1. A round table with all investors, insights exchange
2. An exploration of the exclusive opportunity of Telexos
3. Following the live presentation from the founders, investors will engage in a collaborative feedback and co-development session.
4. The session will conclude with a series of one-to-one investors’ meetings, allowing for deeper conversations with the founders and with like-minded leaders.

About the opportunity: The technology is nearly market-ready and poised to redefine the global diagnostics landscape.

It has developed a non-invasive liquid biopsy technology capable of detecting, isolating and characterizing all circulating tumor cells (CTCs) in a blood sample with unprecedented precision. The platform can identify a single CTC among 40 billion cells (in just 8ml of blood), a level of sensitivity that significantly outperforms existing technologies and traditional tissue-based methods.

This advancement enables earlier detection, faster clinical decision-making and highly personalized cancer care, while reducing both costs and time-to-treatment.  

Breaking down the numbers: The founders are now raising $10M (minimum ticket: $0.5M) to fast-track commercialization, expand operations and accelerate revenue generation. Their clear strategic objective is to position the company for acquisition by a major diagnostics or pharmaceutical player within the next three years.

The 216th Co-Investing Atrium will be held via Zoom, running for 2 hours (4–6 PM Dubai / 8–10 AM New York / 2–4 PM Zurich time).